A comparison of transcatheter aortic valve prosthesis platforms : Myval, Sapien, and Evolut in severe symptomatic aortic stenosis and low-moderate risk patients

Bunc, Matjaž (author), Steblovnik, Klemen (author), Terseglav, Simon (author), Ambrožič, Jana (author), Bervar, Mojca (author), Dimitrovska, Ljupka (author), Čerček, Miha (author), Kovač, Ana (author), Mohorko-Pleskovič, Patricija (author), Kogoj, Polonca (author), Fras, Zlatko (author), Šušteršič, Miha (author), Vrtovec, Bojan (author)

Background This article compares the real-world performance and safety of the three transcatheter aortic valve implantation (TAVI) platforms: Myval, Sapien, and Evolut in patients with severe symptomatic aortic stenosis and low to moderate surgical risk. Patients and methods Between September 2019 and September 2023, 1053 TAVI procedures were performed in the University Medical Centre Ljubljana, Slovenia. We used propensity-score match analysis to compare the Myval, Sapien, and Evolut platforms. 180 patients were enrolled in the propensity-score matching study, 60 for each platform. The study endpoints included haemodynamic outcomes compared to baseline, in-hospital clinical safety outcomes, and all-cause mortality at 30 days and one year. Results Changes in peak aortic valve velocity, mean aortic gradient, effective orifice area, and left ventricular ejection fraction were comparable between the platforms. After propensity score matching (tri-match), the rates of stroke (3.4% vs. 3.4% vs. 0.0%, p = 0.548), life-threatening bleeding (1.7% vs. 1.7% vs. 1.7 %), periprocedural myocardial infarction (3.3% vs. 0.0% vs. 0.0%, p = 0.330), postprocedural permanent pacemaker implantation rate (11.9% vs. 10.2% vs. 15.0%, p = 0.719), all-cause mortality at 30 days (3.3% vs. 5.0% vs. 3.3%; p = 1.000) and at 1 year (8.3% vs. 8.3% vs. 10.0%, p = 0.934) were comparable between the Myval, Sapien, and Evolut series, respectively. 2 cases of moderate paravalvular regurgitation were reported, one in Myval, and one in Sapien series. Conclusions The tri-match analysis of the real-world aortic stenosis patients with low to moderate surgical risk treated with the Myval, Sapien, and Evolut series showed comparable performance, safety, efficacy, and survival.

• Language: English
• Keywords: transcatheter aortic valve implantation, aortic stenosis, real-world comparison
• Work type: Article
• Typology: 1.01 - Original Scientific Article
• Organization: MF - Faculty of Medicine
• Publication status: Published
• Publication version: Version of Record
• Year: 2025
• Number of pages: Str. 498-509, IV
• Numbering: Vol. 59, no. 4
• PID: 20.500.12556/RUL-185581
• UDC: 616.126
• ISSN on article: 1318-2099
• DOI: 10.2478/raon-2025-0046
• COBISS.SI-ID: 271727107
• Publication date in RUL: 11.08.2026

Record is a part of a journal

• Title: Radiology and oncology
• Shortened title: Radiol. oncol.
• Publisher: Association of Radiology and Oncology
• ISSN: 1318-2099
• COBISS.SI-ID: 32649472

Licences

• License: CC BY 4.0, Creative Commons Attribution 4.0 International
• Link: http://creativecommons.org/licenses/by/4.0/
• Description: This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

• Language: Slovenian
• Title: Primerjava perkutanih aortnih zaklopk Myval, Sapien in Evolut pri simptomatskih bolnikih z aortno stenozo in nizkim do zmernim kirurškim tveganjem
• Keywords: perkutana zamenjava aortne zaklopke, aortna stenoza